A Phase III, Randomized, Observer-Blind Study to Evaluate the Safety and Superiority in Immunogenicity of PTX-COVID19-B Administered as Booster Vaccination Compared to Vaxzevria® in Adults Aged 18 Years and Older Who Were Previously Vaccinated With Vaxzevria®

Everest Medicines (Singapore) Pte. Ltd.0 sites450 target enrollmentFebruary 3, 2023

ConditionsSARS-CoV-2 Infection

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: SARS-CoV-2 Infection
Sponsor: Everest Medicines (Singapore) Pte. Ltd.
Enrollment: 450
Primary Endpoint: Immunogenicity Response
Status: Not yet recruiting
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

This is a Phase III, Randomized, Observer-Blind Study to Evaluate the Safety and Superiority in Immunogenicity of PTX-COVID19-B Administered as Booster Vaccination Compared to Vaxzevria® in Adults Aged 18 Years and Older Who Were Previously Vaccinated with Vaxzevria®.

This study will be a competitive enrollment process in all participating countries. Once the target number of subjects is reached, the enrollment in all participating countries in the particular phase will be stopped.

Registry

clinicaltrials.gov

Start Date

February 3, 2023

End Date

October 18, 2023

Last Updated

3 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Everest Medicines (Singapore) Pte. Ltd.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subject is willing and able to provide written informed consent and can understand and agree to comply with the requirements of the study and the schedule of assessments.
•Adult males and females 18 years of age or older on the day of signing the ICF (or the legal age of consent in the jurisdiction in which the study is taking place) in general good health before study participation with no clinically relevant abnormalities (at Investigator's discretion) that could interfere with study assessments. Subjects may have stable comorbidities (no change in medications, exacerbations, or hospitalizations in the past 3 months).
•Documented evidence of previous primary vaccination with 2 doses of Vaxzevria® at least 3 months prior to the ICF date.
•SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR)-negative at screening.
•Body mass index of ≥ 18 and ≤ 30 kg/m2 at screening.
•Women of childbearing potential (WOCBP) and men whose sexual partners are WOCBP must be able and willing to use at least 1 highly effective method of contraception (i.e., including hysterectomy, bilateral salpingectomy, and bilateral oophorectomy, hormonal oral \[in combination with male condoms with spermicide\], transdermal, implant, or injection, barrier \[i.e., condom, diaphragm with spermicide\]; intrauterine device; vasectomized partner \[6 months minimum\], clinically sterile partner; or abstinence) during the study or 6 months after the last study vaccine, whichever later.
•A female subject is considered a WOCBP after menarche and until she is in a postmenopausal state for 12 consecutive months (without an alternative medical cause) or otherwise permanently sterile.
•Subjects not of childbearing potential are not required to use any other forms of contraception during the study. Non-childbearing potential is defined as subject confirmed: i. Surgical sterilization (e.g., bilateral oophorectomy, bilateral salpingectomy, bilateral occlusion by cautery \[Essure System® is not acceptable\], hysterectomy, or tubal ligation). ii. Postmenopausal (defined as permanent cessation of menstruation for at least 12 consecutive months prior to screening); if postmenopausal status is unclear, pregnancy tests will be performed prior to vaccinations.
•WOCBP must have a negative pregnancy test before vaccination. If menopausal status is unclear, a pregnancy test is required.

Exclusion Criteria

•Individuals who are antigen positive, seropositive or reverse transcriptase polymerase chain reaction (RT-PCR) positive for SARSCoV-
•Women currently pregnant, lactating, or planning a pregnancy within 3 months post boost vaccine.
•Any medically diagnosed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination including known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV).
•Receipt of an organ or bone marrow transplant; or Long-term (\>2 weeks) use of oral or parenteral steroids or high-dose inhaled steroids (\>800 μg/day of beclomethasone dipropionate or equivalent) within 6 months before screening (nasal and topical steroids are allowed).
•History of Guillain-Barré Syndrome or any degenerative neurology disorder, or myocarditis, pericarditis.
•History of anaphylactic-type reaction to any injected vaccines; or known or suspected hypersensitivity to 1 or more of the components of the vaccine.
•Acute illness or fever (axillary temperature ≥ 37.5ºC or oral temperature ≥ 38.0ºC) within 3 days (72 hours) before study enrollment (enrollment may be delayed for full recovery if acceptable to the investigator).
•Congenital or functional absence of spleen, complete or partial removal of spleen in any case.
•Donate or loss ≥ 450 ml of blood within 1 month prior to enrollment or expected blood donation during the study.
•Individuals currently participating or planning to participate in a study that involves an experimental agent (vaccine, drug, biologic, device, or medication); or who have received an experimental agent within 1 month (3 months for immunoglobulins) before enrollment in this study; or who expect to receive another experimental agent during participation in this study.

Outcomes

Primary Outcomes

Immunogenicity Response

Time Frame: Day15

To demonstrate that the immune response of a single booster dose of PTXCOVID19-B is superior to that of Vaxzevria® at Day 15 in adults 18 years of age and older.